消化器系癌患者におけるS-1の薬物動態および薬力学的研究

基本情報

NCT ID

NCT00197431

ステータス

不明

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

-

治験依頼者名

Hamamatsu University

概要

S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. 5-FU is metabolized by CYP2A6 and DPD. In this study, the researchers investigate the influences of differences in activities of CYP2A6 and DPD on pharmacokinetics and pharmacodynamics of S-1 and clinical outcomes in digestive organ cancer patients treated with S-1.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)